The Epidemiology And Treatment Of Infections Due To Multiresistant Gram Negative Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$274,946.00
Summary
This fellowship application deals with the treatment of infections due to antibiotic resistant bacteria. The World Economic Forum recently discussed threats to our modern way of life. The highest ranked threats were climate change, terrorism and antibiotic resistance. During this Fellowship, two large clinical trials of treatment strategies for antibiotic resistant bacteria will be supervised by Professor Paterson.
Optimisation Of Beta-lactam Antibiotic Therapy As A Strategy To Improve Efficacy And Combat The Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Antibiotic resistance is a global health priority that threatens to compromise advances in modern medicine to return practices to the pre-antibiotic era. Critically ill and patients with impaired immune function represent a vulnerable group who struggle to fight infections and who rely heavily on lifesaving antibiotics. This project aims to investigate how the efficacy of antibiotics can be optimised to prevent the emergence of resistance and preserve their effectiveness for the future.
Vancomycin is the antibiotic we rely on for the treatment of major infections due to bacteria that are resistant to other antibiotics (MRSA). Vancomycin is monitored in each patient to individualise the dose. This is done to improve treatment efficacy, reduce adverse effects and to prevent antibiotic resistance. This project will introduce a vancomycin guideline and train hospital staff to use vancomycin safely, effectively and to minimise the development of resistance.
Antibiotics have different effects on our own bacterial ecology, with sometimes unexpected detrimental effects. In this project, we will study this in detail and particularly address the question of 'good' and 'bad' antibiotics and how to identify them. National antibiotic policy and the deployment of 'decontamination' strategies in the critically ill are directly related issues and we expect to inform these important policy debates.
Prof Paterson is an Infectious Diseases Physician studying the molecular and clinical epidemiology of infections with Gram negative bacteria producing newer beta-lactamases.
Centre Of Research Excellence In Indigenous Children's Healthy EARs (ICHEAR)
Funder
National Health and Medical Research Council
Funding Amount
$2,615,897.00
Summary
The overwhelming burden of otitis media (middle ear inflammation, OM) and the consequences of hearing loss on social and educational outcomes in Indigenous children are indisputable. Our CRE_ICHEAR is a multidisciplinary group of Australia’s experts in OM research, policy and practice guidelines. The CRE will derive better value in terms of discovery, translation and sustainability. Increased Indigenous leadership will raise awareness and advocacy, with greater efficiency of research translation
Intensive Care patients more often than not, develop kidney failure requiring dialysis. Unfortunately there is little information available to inform clinicians of appropriate doses for antibiotics in these patients, putting them at an increased risk of death from ineffective treatment. Our project aims to develop dosing guidelines for the many types of dialysis used globally to achieve concentrations in the blood that optimise antibiotic effects in these most critically ill patients.
Addressing Important Evidence Gaps In The Management Of Severe Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$256,839.00
Summary
There are currently large gaps in the evidence base for management of common severe bacterial infections. My research plan focuses on the most common of these: Staphylococcus aureus infections, bone and joint infections, skin infections, and severe sepsis. In order to both generate important evidence to inform practice, as well as to develop my own skills and experience as an expert in clinical trials, I have initiated randomised controlled trials in each of these areas.
A Prospective, Randomised, Double-blind Trial Of Extended- Versus Bolus-infusion ?-lactam Therapy In Infective Exacerbations Of Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$148,431.00
Summary
I am an infectious diseases physician focused on the most effective way to use antibiotics to treat infections. People with cystic fibrosis often get lung infections and the bacteria that causes this, Pseudomonas aeruginosa, can be difficult to treat. I will be investigating whether infusing antibiotics over a prolonged period of time is more effective than standard therapy in treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.